Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010

Background/purpose Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient...

Full description

Saved in:

Bibliographic Details
Published in:	Graefe's archive for clinical and experimental ophthalmology Vol. 251; no. 11; pp. 2499 - 2503
Main Authors:	Cohen, Salomon Y., Dubois, Lise, Ayrault, Sandrine, Dourmad, Pauline, Delahaye-Mazza, Corinne, Fajnkuchen, Franck, Nghiem-Buffet, Sylvia, Quentel, Gabriel, Tadayoni, Ramin
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2013 Springer Nature B.V
Subjects:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Exudates and Transudates Female Fluorescein Angiography Humans Intravitreal Injections Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab Retinal Disorders Retrospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology Exudative age-related macular degeneration Real-life retrospective study Ranibizumab
ISSN:	0721-832X, 1435-702X, 1435-702X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!